Inside the Semaglutide Supply Chain: How the World’s Best-Selling Drug Gets Made

Executive Summary

Semaglutide (Ozempic, Wegovy, Rybelsus) generated $38.7 billion in revenue across Novo Nordisk’s portfolio in 2025, making it the highest-selling drug in the world. Behind that commercial success lies the most complex peptide manufacturing operation ever built — a global supply chain spanning four continents, consuming 6.4 metric tons of peptide API annually, involving over 15,000 raw material suppliers, and requiring $16.5 billion in capital investment for capacity expansion. This analysis maps how the world’s best-selling drug gets made — and the vulnerabilities in that supply chain.

The Molecule: Complexity as a Moat

Semaglutide is a 31-amino acid GLP-1 analog conjugated to a C-18 fatty diacid via a hydrophilic linker at Lys26. Three structural features make it challenging to manufacture. The lipidation (attachment of the fatty acid chain) is the most synthetically demanding step — it requires selective deprotection of Lys26 while leaving other lysine side chains protected, a regioselectivity challenge that adds 4–6 synthetic steps compared to unlipidated GLP-1 analogs. The alpha-aminoisobutyric acid (Aib) residue at position 8, while conferring DPP-4 resistance, is a sterically hindered amino acid that couples with 5–10× lower efficiency than canonical residues. The overall length (31 residues) places semaglutide in the “medium-long” peptide category, where each additional residue exponentially increases the impurity burden.

Novo Nordisk has filed over 40 patents covering specific aspects of semaglutide manufacturing, including the coupling sequence, protecting group strategy, cleavage conditions, and purification methods. This patent thicket — extending to 2034 in some jurisdictions — is a deliberate competitive moat that will outlast the primary composition-of-matter patent expiry in 2027.

Manufacturing Geography

Novo Nordisk’s semaglutide manufacturing is distributed across four production sites: Kalundborg, Denmark (2.8 tons/year capacity, the original and largest facility), Clayton, North Carolina (1.2 tons/year, operational since 2023), Chartres, France (under construction, 2.0 tons/year target, expected 2027), and Bloomington, Indiana (acquired from Catalent in 2024, 0.8 tons/year, being expanded to 1.5 tons/year). Combined, these sites will provide approximately 7.5 metric tons of annual semaglutide API capacity by 2028 — representing a roughly 3× increase from 2023 levels.

The fill-finish operation — converting peptide API into injection pens — is an equally critical capacity constraint. Each Ozempic/Wegovy injection pen contains 0.25–2.4 mg of semaglutide in a sterile solution. Novo Nordisk produces over 800 million injection pens annually across facilities in Denmark, France, Brazil, China, Japan, and the United States. The sterile filling lines represent a capital investment of $200–400 million per line and require 18–24 months to qualify. Novo Nordisk has committed to building 12 new filling lines by 2028.

Raw Material Supply Chain

Semaglutide manufacturing consumes approximately 50–80 metric tons of protected amino acids annually, sourced primarily from three suppliers: Bachem (Switzerland), CordenPharma (Germany/Colorado), and Watanabe Chemical (Japan). The most critical raw materials — Fmoc-Lys(Alloc)-OH (for selective Lys26 deprotection) and the C-18 fatty diacid linker — are single-sourced, representing a concentration risk that Novo Nordisk has identified in its SEC filings.

The acetonitrile supply for preparative HPLC — approximately 80–120 million liters annually — is sourced from INEOS and Asahi Kasei. Acetonitrile is a byproduct of acrylonitrile manufacturing, and global supply can be disrupted by acrylonitrile plant outages. The 2024 INEOS Cologne plant shutdown reduced European acetonitrile supply by 15% for six weeks, causing a spike in spot prices from $2.50 to $12.00 per liter — a supply chain vulnerability that few outside the industry appreciate.

Expert Insight: The Biosimilar Challenge

Multiple companies — including Biocon, Viatris, Sandoz, and Teva — are developing semaglutide biosimilars, but they face a daunting manufacturing challenge. To be cost-competitive with Novo Nordisk (which benefits from two decades of process optimization and massive economies of scale), a biosimilar entrant must achieve comparable manufacturing costs from day one — without access to Novo Nordisk’s proprietary process knowledge, optimized cell lines, or supply chain relationships.

What experienced peptide manufacturers understand: The patent expiry of semaglutide in 2027–2034 is not a single event — it is a phased process. The primary composition-of-matter patent expires first, but manufacturing process patents (covering the specific protecting group strategy, coupling sequence, and purification method) extend to 2032–2034. A biosimilar manufacturer cannot simply copy Novo Nordisk’s process — they must develop an alternative process that achieves comparable purity without infringing the process patents. This is an expensive exercise (estimated $200–400 million in development costs) that only the largest generic manufacturers can afford. The likely outcome: 3–4 semaglutide biosimilars entering the market between 2028 and 2032, with 20–40% price reduction — not the 80–90% price reduction typical of small-molecule generics.

Frequently Asked Questions

Why is semaglutide still in shortage if Novo Nordisk is investing $16.5B in capacity?

Peptide manufacturing capacity cannot be turned on quickly. A new SPPS production line requires 3–4 years from ground-breaking to FDA qualification. The capacity currently being built addresses the demand that Novo Nordisk forecasts for 2028–2030, not today’s demand. The shortage will persist until at least late 2027, when the Clayton expansion and Chartres facility come online.

Could semaglutide be manufactured by a different method?

Yes, but switching manufacturing methods for an approved drug requires a post-approval change that the FDA reviews as a Prior Approval Supplement (PAS) — a 6–12 month regulatory process. Novo Nordisk has investigated recombinant expression (in yeast), enzymatic semisynthesis, and flow chemistry as alternatives to batch SPPS, but the regulatory burden of switching a $38 billion drug to a new manufacturing process creates enormous inertia. Any alternative method would likely be deployed for a next-generation GLP-1 analog rather than for semaglutide itself.

Further Reading

• The Peptide CDMO Landscape — who else can manufacture at this scale
• Economics of Peptide Manufacturing — cost structure details
• The Peptide Patent Cliff — what happens when semaglutide’s patents expire

Last reviewed: June 2026. Peptide Proof Editorial Team.